Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.

AIM To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20618 patients. METHODS Pooled risk differences (RD) for rivaroxaban vs enoxaparin and dabigatran vs enoxaparin obtained from separate meta-analyses of two sets of trials were used to indirectly estimate RDs for rivaroxaban vs dabigatran. RESULTS Primary efficacy (any VTE+all-cause mortality) and safety (major bleeding) outcomes in enoxaparin arms largely differed across similarly designed rivaroxaban and dabigatran trials (differences in venography adjudication and bleeding events definitions). However, incidence of symptomatic VTE and incidence of major/non-major clinically relevant bleeding (including surgical site) were consistent in this respect. RDs (as percentages) for symptomatic VTE were: rivaroxaban-enoxaparin=-0.4% (95% confidence interval [CI], -0.9 to 0.05); dabigatran-enoxaparin=-0.09% (95% CI, -1.0 to 0.8); rivaroxaban-dabigatran=-0.3% (95% CI, -1.3 to 0.7; P=0.275). RDs for major/clinically relevant bleeding were rivaroxaban-enoxaparin=0.99% (95%CI, 0.29 to 1.69); dabigatran-enoxaparin=0.02% (95% CI, -1.0 to 1.0); rivaroxaban-dabigatran=0.97 (95% CI, -0.43 to 2.37; P=0.085). Mortality rates (all-cause, VTE-related, bleeding-related) were very low not indicating differences between any two of the three treatments. CONCLUSION Methodological differences disable indirect comparisons of rivaroxaban vs dabigatran that would be based on major efficacy/safety outcomes of their pivotal trials. The two drugs do not seem to differ regarding incidence of symptomatic VTE. Risk of a relevant bleeding is higher with rivaroxaban than with enoxaparin and the same tendency exists also vs dabigatran. Direct rivaroxaban vs dabigatran comparisons in this setting are needed.

• Publication year

  2010

• Venue

  Croatian Medical Journal

• Publication date

  2010-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.3325/CMJ.2010.51.113PMID 20401953PMCID PMC2867548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting

  2012cited by this paper
• Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

  2009cited by this paper
• Use of Emerging Oral Anticoagulants in Clinical Practice: Translating Results from Clinical Trials to Orthopedic and General Surgical Patient Populations

  2009cited by this paper
• State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis

  2009cited by this paper
• Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

  2009cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

  2009cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper
• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  2008cited by this paper
• Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  2008cited by this paper
• Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study

  2007cited by this paper
• Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

  2007cited by this paper
• Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

  2007cited by this paper
• Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery

  2007cited by this paper
• Indirect comparisons of competing interventions.

  2005cited by this paper
• Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery?

  2005cited by this paper
• Interaction revisited: the difference between two estimates

  2003cited by this paper
• Early postoperative mortality after 67,548 total hip replacements

  2002cited by this paper
• Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register

  2000cited by this paper

• Current Evidence and Expert Opinion on Thromboprophylaxis After Total Knee and Hip Replacement

  2023cites this paper
• Efficacy and Safety of Enoxaparin versus New Oral Anticoagulants to Prevent Venous Thromboembolism after Total Hip Replacement: A Systematic Review and Meta-Analysis

  2022cites this paper
• A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.

  2020cites this paper
• Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients

  2019cites this paper
• Effectiveness of Alternating Thromboprophylaxis from Enoxaparin to Rivaroxaban after Total Knee Arthroplasty

  2019cites this paper
• Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis

  2018cites this paper
• Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta‐analysis

  2017cites this paper
• Warfarin should not be used for thromboprohylaxis in elective major orthopaedic surgery: a Croatian perspective.

  2017cites this paper
• Topical Tranexamic Acid Reduces Blood Loss in Minimally Invasive Total Knee Arthroplasty Receiving Rivaroxaban

  2017cites this paper
• The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.

  2017cites this paper
• Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date

  2016cites this paper
• Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues.

  2016cites this paper
• Rivaroxaban versus Dabigatran: A new era in venous thromboembolism treatment

  2016cites this paper
• Clinical Experience With Novel Oral Anticoagulants for Thromboprophylaxis After Elective Hip and Knee Arthroplasty

  2015cites this paper
• Venous thromboembolism in Croatia – Croatian Cooperative Group for Hematologic Diseases (CROHEM) study

  2015cites this paper
• Physico-chemical characterization and the in vitro genotoxicity of medical implants metal alloy (TiAlV and CoCrMo) and polyethylene particles in human lymphocytes.

  2014cites this paper
• Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban

  2013cites this paper
• Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2013cites this paper
• Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians

  2013cites this paper
• Clinical trials with new oral anticoagulants

  2013cites this paper
• Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)

  2013cites this paper
• The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty

  2013cites this paper
• Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.

  2013cites this paper
• Klinische Studien zu neuen direkten oralen Antikoagulanzien Clinical trials with new direct oral anticoagulants

  2013cites this paper
• University of Groningen Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery

  2013cites this paper
• Clinical trials with new direct oral anticoagulants Additive value of indirect comparisons also named network meta-analyses

  2013cites this paper
• Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxaban

  2013cites this paper
• Apixaban: a novel oral inhibitor of factor Xa.

  2012cites this paper
• Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

  2012cites this paper
• New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders

  2012cites this paper
• Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

  2012cites this paper
• Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants.

  2012cites this paper
• Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery

  2012cites this paper
• Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.

  2012cites this paper
• Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

  2012cites this paper
• Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis

  2012cites this paper
• Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.

  2012cites this paper
• Dabigatran Etexilate: A Possible Replacement for Heparinoids and Vitamin K Antagonists?

  2011cites this paper
• Characteristics of novel anticoagulants and potential economic implications.

  2011cites this paper
• Perioperative management of proximal hip fractures in the elderly: the surgeon and the anesthesiologist.

  2011cites this paper
• An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement

  2011cites this paper
• Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update

  2011cites this paper
• prevention and Treatment of Venous Thromboembolic events: Focus on Dabigatran etexilate

  2011cites this paper
• Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

  2011cites this paper
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty

  2011cites this paper
• Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban

  2011cites this paper
• SVEUĈILIŠTE U ZAGREBU

  2010cites this paper